Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
Vedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin and selectively blocks gut-specific lymphocyte trafficking. Although upper respiratory tract infections (URTIs) have been reported with VDZ [1] its gut selectivity may reduce the risk of respiratory tract infections (RT...
| Hoofdauteurs: | , , , , , , |
|---|---|
| Formaat: | Journal article |
| Gepubliceerd in: |
Oxford University Press
2017
|